Tensegrity Pharma and argenx Collaborate on Innovative TSP-101 Research Tensegrity Pharma has entered into a collaboration with argenx for the research and development of TSP-101, targeting immune diseases.

Tensegrity Pharma and argenx Collaborate on Innovative TSP-101 Research #Japan #Tokyo #TSP-101 #Tensegrity_Pharma #argenx

テンセグリティファーマとargenxが画期的な共同研究契約を締結 テンセグリティファーマとargenxが、TSP-101の研究開発を共同で推進する契約を締結しました。新たな治療法の開発に期待が寄せられています。

テンセグリティファーマとargenxが画期的な共同研究契約を締結 #テンセグリティファーマ #TSP-101 #argenx

テンセグリティファーマとargenxが、TSP-101の研究開発を共同で推進する契約を締結しました。新たな治療法の開発に期待が寄せられています。

免疫疾患に立ち向かう！テンセグリティファーマがargenxとTSP-101の共同研究契約を締結 テンセグリティファーマとargenxがTSP-101の共同開発契約を結成。免疫疾患治療の新たな光を探ります。

免疫疾患に立ち向かう！テンセグリティファーマがargenxとTSP-101の共同研究契約を締結 #東京都 #中央区 #テンセグリティファーマ #TSP-101 #argenx

テンセグリティファーマとargenxがTSP-101の共同開発契約を結成。免疫疾患治療の新たな光を探ります。

Pharmalittle: We're reading about an AbbVie deal for a psychedelic, Lilly obesity pill trial results, and more AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major depression

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an AbbVie deal for a psychedelic, Lilly obesity pill trial results & Much more news.. statnews.com/pharmalot/20... #pharma #psychedelic #obesity #weight #diabetes #FDA #patents #HIV #Gilead #AbbVie #Gilead #Argenx

Argenx stock falls after FDA flags serious risk signal with Vyvgart Investing.com -- Argenx NV ADR (NASDAQ:ARGX) stock tumbled 6% after the U.S. Food and Drug Administration (FDA) identified a potential serious risk associated with the company’s lead drug, Vyvgart. The FDA published a report highlighting a "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" as a potential signal of serious risk with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection. The regulatory agency stated it is currently evaluating the need for regulatory action. Vyvgart is Argenx’s flagship product, approved for treating generalized myasthenia gravis, a rare autoimmune disease. The identification of this safety concern comes at a critical time for the company, which has been positioning the medication as a key growth driver. The FDA regularly monitors approved drugs for potential safety issues that weren’t identified during clinical trials. When a potential signal is detected, the agency conducts further investigation to determine whether regulatory action is warranted, which could range from label updates to more significant restrictions. Investors reacted to the news by selling shares, reflecting concerns about potential impacts on Vyvgart’s commercial prospects should the FDA determine that additional warnings or limitations are necessary. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Argenx #Vyvgart #FDANews #StockMarket #Investing

Argenx presents new efgartigimod data at EULAR 2025 - PharmaTimes Rheumatology studies show promising results for Sjogren’s disease

#pharmaceuticals #Rheumatology #NeuromuscularDisease #Argenx #efgartigimod #efgartigimoddata #EULAR2025 #Sjogrensdisease #myositis #FastTrackdesignation #primarySjogrensdisease #ALKIVIAstudy #myositispatients #FcRninhibitor #UNITYtrial
pharmatimes.com/news/argenx-...

Argenx receives positive CHMP opinion for CIDP treatment - PharmaTimes VYVGART could be the first CIDP drug with a novel mechanism in 30 years

#Argenx #CHMP #CIDPtreatment #VYVGART #efgartigimodalfa #chronicinflammatorydemyelinatingpolyneuropathy #CIDPdrug #ADHEREtrial #CIDPclinicalstudy #IgGFcantibodyfragment #immunoglobulintherapy #CIPDpatients #EPODIN #CIPDmanagement #CHMPrecommendation #CHMPopinion
pharmatimes.com/news/argenx-...